CG Oncology, Inc. Common stock (CGON) NASDAQ
53.72
-2.37(-4.23%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
53.72
-2.37(-4.23%)
Currency In USD
Address
400 Spectrum Center Drive
Irvine, DE
United States of America (the)
Phone
+1 949 354 1630
Website
Sector
Healthcare
Industry
Biotechnology
Employees
113
First IPO Date
January 25, 2024
| Name | Title | Pay | Year Born |
| Arthur Kuan | Chairman & Chief Executive Officer | 1.13M | 1991 |
| Joshua F. Patterson | General Counsel, Chief Compliance Officer & Secretary | 693,819 | 1977 |
| Vijay Kasturi | Chief Medical Officer | 759,983 | 1968 |
| James DeTore | Chief Financial Officer | 785,472 | 1965 |
| Ambaw Bellete | President & Chief Operating Officer | 847,791 | 1971 |
| Bing Kung | Vice President of Corporate Development | 0 | N/A |
| Swapnil Bhargava | Chief Technical Officer | 0 | N/A |
| Amy Steele | Vice President of Finance & Administration | 0 | N/A |
| Sarah Connors | Vice President of Communications & Patient Advocacy | 0 | N/A |
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.